{"id": "chatcmpl-8JYRqOGLZ1oIjt2CJ4IxaOApqwTOF", "object": "chat.completion", "created": 1699671342, "model": "gpt-4-0613", "choices": [{"index": 0, "message": {"role": "assistant", "content": "1. The duration of effect was modestly diminished with alirocumab plus ezetimibe/fenofibrate versus placebo.\n2. The effect was less than observed in trials with background statins.\n3. The diminished effect would not preclude the use of alirocumab every 4 weeks.\n4. The statement refers to patients taking nonstatin lipid\u2010lowering therapies concomitantly.\n5. Alirocumab can be used in conjunction with ezetimibe/fenofibrate.\n6. Alirocumab can be used every 4 weeks."}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 101, "completion_tokens": 119, "total_tokens": 220}, "temperature": 0, "max_tokens": 512, "top_p": 1, "frequency_penalty": 0, "presence_penalty": 0, "messages": [{"role": "system", "content": "Statement: Although the duration of effect was modestly diminished with alirocumab plus ezetimibe/fenofibrate versus placebo, the effect was less than observed in trials with background statins, and it would not preclude the use of alirocumab every 4 weeks in patients taking these nonstatin lipid\u2010lowering therapies concomitantly.\n\nList all the facts we explicitly know from the statement. Make each fact as atomic as possible."}]}